For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
In the latest session, Conmed Corp (NYSE: CNMD) closed at $55.81 up 5.16% from its previous closing price of $53.07. In other words, the price has increased by $5.16 from its previous closing price. On the day, 0.51 million shares were traded. CNMD stock price reached its highest trading level at $56.12 during the session, while it also had its lowest trading level at $53.35.
Ratios:
For a deeper understanding of Conmed Corp’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 50.89 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 11.65. For the most recent quarter (mrq), Quick Ratio is recorded 1.00 and its Current Ratio is at 2.23. In the meantime, Its Debt-to-Equity ratio is 0.88 whereas as Long-Term Debt/Eq ratio is at 0.88.
On April 28, 2025, Stifel Downgraded its rating to Hold which previously was Buy but kept the price unchanged to $55.
JP Morgan Downgraded its Overweight to Neutral on February 06, 2025, whereas the target price for the stock was revised from $85 to $70.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 07 ’25 when Garner Todd W sold 598 shares for $52.45 per share. The transaction valued at 31,365 led to the insider holds 0 shares of the business.
Garner Todd W bought 598 shares of CNMD for $31,365 on Aug 07 ’25. On May 05 ’25, another insider, Farkas Charles, who serves as the Director of the company, sold 4,000 shares for $56.94 each. As a result, the insider received 227,768 and left with 16,346 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CNMD now has a Market Capitalization of 1727598592 and an Enterprise Value of 2575486464. As of this moment, Conmed’s Price-to-Earnings (P/E) ratio for their current fiscal year is 15.76, and their Forward P/E ratio for the next fiscal year is 11.77. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.83. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.31 while its Price-to-Book (P/B) ratio in mrq is 1.72. Its current Enterprise Value per Revenue stands at 1.942 whereas that against EBITDA is 11.703.
Stock Price History:
The Beta on a monthly basis for CNMD is 1.18, which has changed by -0.2287175 over the last 52 weeks, in comparison to a change of 0.1513431 over the same period for the S&P500. Over the past 52 weeks, CNMD has reached a high of $78.19, while it has fallen to a 52-week low of $46.00. The 50-Day Moving Average of the stock is 7.06%, while the 200-Day Moving Average is calculated to be -8.11%.
Shares Statistics:
For the past three months, CNMD has traded an average of 456.02K shares per day and 446590 over the past ten days. A total of 30.95M shares are outstanding, with a floating share count of 30.07M. Insiders hold about 2.86% of the company’s shares, while institutions hold 111.55% stake in the company. Shares short for CNMD as of 1753920000 were 2096118 with a Short Ratio of 4.60, compared to 1751241600 on 2273055. Therefore, it implies a Short% of Shares Outstanding of 2096118 and a Short% of Float of 9.25.
Dividends & Splits
According to the company, the forward annual dividend rate for CNMD is 0.80, from 0.8 in the trailing year. Against a Trailing Annual Dividend Yield of 0.01507443The stock’s 5-year Average Dividend Yield is 0.88. The current Payout Ratio is 18.82% for CNMD, which recently paid a dividend on 2025-06-13 with an ex-dividend date of 2025-09-15. Stock splits for the company last occurred on 2001-09-10 when the company split stock in a 3:2 ratio.
Earnings Estimates
The current rating of Conmed Corp (CNMD) is the result of assessments by 6.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is $1.32, with high estimates of $1.36 and low estimates of $1.27.
Analysts are recommending an EPS of between $4.5 and $4.43 for the fiscal current year, implying an average EPS of $4.47. EPS for the following year is $4.78, with 6.0 analysts recommending between $4.99 and $4.5.
Revenue Estimates
A total of 6 analysts believe the company’s revenue will be $334.76M this quarter.It ranges from a high estimate of $337.3M to a low estimate of $332.5M. As of the current estimate, Conmed Corp’s year-ago sales were $316.7MFor the next quarter, 6 analysts are estimating revenue of $369.1M. There is a high estimate of $370.7M for the next quarter, whereas the lowest estimate is $367.69M.
A total of 6 analysts have provided revenue estimates for CNMD’s current fiscal year. The highest revenue estimate was $1.37B, while the lowest revenue estimate was $1.37B, resulting in an average revenue estimate of $1.37B. In the same quarter a year ago, actual revenue was $1.31BBased on 6 analysts’ estimates, the company’s revenue will be $1.44B in the next fiscal year. The high estimate is $1.46B and the low estimate is $1.42B.
